ReviewCNS drugs2014
Novel therapeutic strategies for traumatic brain injury: acute antioxidant reinforcement.
Review in CNS drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 65 citations in OpenAlex.
- Therapeutic potential of alpha-tocopherol in reducing oxidative stress and inflammatory damage after experimental traumatic brain injury and pentylenetetrazol-induced seizures.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mitochondrial and ER stress crosstalk in TBI: mechanistic insights and therapeutic opportunities.Frontiers in cellular neuroscience · 2025Review
- Mitochondria-Targeted Antioxidant Therapeutics for Traumatic Brain Injury.Antioxidants (Basel, Switzerland) · 2024Review
- Reactive gliosis in traumatic brain injury: a comprehensive review.Frontiers in cellular neuroscience · 2024Review
- Electroacupuncture Inhibits Neural Ferroptosis in Rat Model of Traumatic Brain InjuryCurrent neurovascular research · 2024Article
- Traumatic Brain Injury, Sleep, and Melatonin-Intrinsic Changes with Therapeutic Potential.Clocks & sleep · 2023Review
- The neuroprotective potential of phytochemicals in traumatic brain injury: mechanistic insights and pharmacological implications.Frontiers in pharmacology · 2023Review
- Antioxidant Therapeutic Strategies in Neurodegenerative Diseases.International journal of molecular sciences · 2022Review
- Physical Activity vs. Redox Balance in the Brain: Brain Health, Aging and Diseases.Antioxidants (Basel, Switzerland) · 2021Review
- MIF promotes neurodegeneration and cell death via its nuclease activity following traumatic brain injury.Cellular and molecular life sciences : CMLS · 2021Article
- Novel Synthetic and Natural Therapies for Traumatic Brain Injury.Current neuropharmacology · 2021Review
- Zinc in the Brain: Friend or Foe?International journal of molecular sciences · 2020Review
- Influence of Organic Solvents on Secondary Brain Damage after Experimental Traumatic Brain Injury.Neurotrauma reports · 2020Article
- Mitochondria-Targeted Antioxidants: A Step towards Disease Treatment.Oxidative medicine and cellular longevity · 2020Review
- Mitochondria-Targeted Antioxidants as Potential Therapy for the Treatment of Traumatic Brain Injury.Antioxidants (Basel, Switzerland) · 2019Article
- N-Acetyl Serotonin Protects Neural Progenitor Cells Against Oxidative Stress-Induced Apoptosis and Improves Neurogenesis in Adult Mouse Hippocampus Following Traumatic Brain Injury.Journal of molecular neuroscience : MN · 2019Article
- Ferroptosis and Brain Injury.Developmental neuroscience · 2018Review
- Correlation between TSC1 gene polymorphism and epilepsy.Experimental and therapeutic medicine · 2017Article
- Review
- Metabolomics reveals the effect of Xuefu Zhuyu Decoction on plasma metabolism in rats with acute traumatic brain injury.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) is the most important cause of disability in individuals under the age of 45 years and thus represents a significant social and economic burden. Evidence strongly suggests that oxidative stress is a cornerstone event leading to and propagating secondary injury mechanisms such as excitotoxicity, mitochondrial dysfunction, apoptosis, autophagy, brain edema, and inflammation. TBI has defied conventional approaches to diagnosis and therapy development because of its heterogeneity and complexity. Therefore, it is necessary to explore alternative approaches to therapy development for TBI. The aim of this review is to present a therapeutic approach for TBI, taking into account the evidence supporting the role for oxidative stress in the pathophysiological processes of secondary brain injury. The role of agents such as mitochondria-targeted antioxidants (melatonin and new mitochondria-targeted antioxidants), nicotinamide adenine dinucleotide phosphate (NADPH) inhibitors (antioxidant vitamins and apocynin), and other compounds having mainly antioxidant properties (hydrogen-rich saline, sulforaphane, U-83836E, omega-3, and polyphenols) is covered. The rationale for innovative antioxidant therapies based on current knowledge and particularly the most recent studies regarding this field is discussed. Particular considerations and translational potential of new TBI treatments are examined and a novel therapeutic proposal for TBI is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.